Ophthalmology Times Europe

At the World Glaucoma Congress (WGC) in Rome, Italy this summer, Ciliatech presented preliminary results of the second 2-year postoperative clinical trial (SAFARI Ⅱ) on its Cilioscleral Interposition Device (CID). The device, a 26% hydrophilic acrylic implant, is designed to lower intraocular pressure without entering the anterior chamber and without bleb…